Review of bevacizumab in the treatment of metastatic breast cancer

European Journal of Cancer, Supplement

Volumn 6, Issue 8, 2008, Pages 13-18

  Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bevacizumab; Chemotherapy; Metastatic breast cancer; VEGF

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; GEMCITABINE; LETROZOLE; NAVELBINE; PACLITAXEL; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN; ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ESTROGEN;

ANGIOGENESIS; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD VESSEL FUNCTION; BRAIN ISCHEMIA; BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTENSION; LUNG EMBOLISM; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT SELECTION; PRIORITY JOURNAL; PROTEINURIA; THROMBOSIS; TREATMENT RESPONSE; ARTERIAL THROMBOEMBOLISM; BLOOD VESSEL; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DRUG ACTIVITY; DRUG WITHDRAWAL; EMBOLISM; HAND FOOT SYNDROME; LUNG CANCER; MONOTHERAPY; NEPHROTIC SYNDROME; OVARY CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

EID: 41849104572     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(08)70285-4     Document Type: Article

References (29)

1. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
2. Gasparini G., Toi M., Gion M., et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89 (1997) 139-147
3. Linderholm B., Grankvist K., Wilking N., Johansson M., Tavelin B., and Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18 (2000) 1423-1431
4. Gasparini G., Toi M., Miceli R., et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 5 (1999) 101-111
5. Borgström P., Gold D., Hillan K., and Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19 (1999) 4203-4214
6. Pham C., Roberts T., van Bruggen N., et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16 (1998) 225-230
7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
8. Relf M., LeJeune S., Scott P., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor b-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57 (1997) 963-969
9. Buteau-Lozano H., Ancelin M., Lardeux B., Milanini J., and Perrot-Applanat M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors a and b. Cancer Res 62 (2002) 4977-4984
10. Guo P., Fang Q., Tao H., et al. Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo. Cancer Res 63 (2003) 4684-4691
11. Jain R. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
12. Willett C., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
13. Tong R., Boucher Y., Kozin S., Winkler F., Hicklin D., and Jain R. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumours. Cancer Res 64 (2004) 3731-3736
14. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
15. Sandler A., Gray R., Perry M., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
16. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
17. Cannistra S., Matulonis U., Penson R., et al. Phase II study of bevacizumab in patients with platinumresistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25 (2007) 5180-5186
18. Cobleigh M., Langmuir V., Sledge G., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30 5 Suppl 16 (2003) 117-124
19. Burstein H., Parker L., Savoie J., et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 76 Suppl 1 (2002) S115 [abstract 446].
20. Pegram M., Yeon C., Ku N., et al. Phase I combined biological therapy of breast cancer using two humanised monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 88 Suppl 1 (2004) S124 [abstract 3039].
21. Traina T., Dickler M., Caravelli J., et al. A phase II trial of letrozole in combination with bevacizumab, an anti VEGF antibody, in patients with hormone receptorpositive metastatic breast cancer. Breast Cancer Res Treat 94 Suppl 1 (2005) S93 [abstract 2030].
22. Ramaswamy B., Elias A., Kelbick N., et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12 (2006) 3124-3129
23. Miller K., Chap L., Holmes F., et al. Randomised phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
24. Sledge G., Miller K., Moisa C., et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol 25 18 Suppl (2007) 1013
25. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-791
26. Marty M., Cognetti F., Maraninchi D., et al. Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 (2005) 4265-4274
27. Link JS, Waisman JR, Jacobs CI, et al. Bevacizumab (Avastin) and albumin bound paclitaxel (Abraxane) treatment in metastatic breast cancer. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 14-17 December, 2006 [abstract 1095].
28. Perez EA, Hillman DW, Kugler JW, et al. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 14-17 December, 2006 [abstract 2069].
29. U.S. National Institutes of Health, Department of Health and Human Services. ClinicalTrials.gov. Available from http://www.clinicaltrials.gov. Accessed 2nd January, 2007.